Slide 1: FY 2023 Financial Results and Business Update
FY 2023 Financial Results and Business Update 21 March 2024
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. 2
Slide 3: Participants on Today's Call
Participants on Today’s Call Hervé Brailly Sonia Quaratino Yannis Morel Frédéric Lombard Arvind Sood PhD MD, PhD PhD MBA Chief Executive Officer ad Chief Medical Officer Chief Operating Officer Chief Financial Officer President of US Operations interim Chairman of the Executive Board 3
Slide 4: Innate's approach: harnessing innate immunity in cancer
Priming and activation (APCs and T cells) Innate’s approach: harnessing innate immunity in cancer Cancer antigen presentation (DCs) Choosing the right targets to leverage the body’s immune response Lymph node Trafficking of 01 Amplification of the innate immune response T cells to tumors Engage NK c
Slide 5: Scientific innovation drives our strategy
Scientific innovation drives our strategy Our ambition – ANKET® & ADC leverage our scientific know-how in innate Build a sustainable Lacutamab Advance our immunity and antibody engineering to business through Drive near-term value innovative develop cancer drugs that improve the Drive near-term valu
Slide 6: Our robust pipeline of proprietary & partnered assets
Our robust pipeline of proprietary & partnered assets Program Target Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Upcoming Milestone Sezary syndrome / MF TELLOMAK (FDA FAST TRACK/EMA PRIME DESIGNATION) MF data 2024 Lacutamab KIR3DL2 PTCL KILT Phase 2 IST with LYSA P roprietary IPH5301 CD73 Cancer
Slide 7: Lacutamab | Development strategy
LACUTAMAB Lacutamab | Development strategy A potential new standard of care in the T-cell lymphomas expressing KIR3DL2 Cutaneous T cell lym phoma TELLOMAK Sézary syndrome Phase 2 Trial Sézary syndrome 80-200 patients Phase 2 >90% KIR3DL2 expression Cohort 1 (N~60) 3 cohorts (N~100) ASH 2023 Minimum
Slide 8: Lacutamab | Sézary syndrome Phase 2 data
LACUTAMAB Lacutamab | Sézary syndrome Phase 2 data Lacutamab in Patients with Relapsed and Refractory Sézary Syndrome: Results from the TELLOMAK Phase 2 Trial Patient characteristics Data cutoff: May 1, 2023 56 post mogamulizumab patients with advanced, highly refractory and heavily pre-treated dise
Slide 9: IPH6501, a novel CD20-targeting tetraspecific NK cell engager
ANKET® IPH6501, a novel CD20-targeting tetraspecific natural killer cell engager issued from ANKET® platform, has started clinical study in B-cell malignancies IPH6501, the first proprietary tetraspecific ANKET® Phase 1/2 first-in-human, multicenter, in Patients With Relapsed and/or Refractory Non-H
Slide 10: ANKET NK cell engager molecules have the potential to strongly control tumor proliferation
ANKET® ANKET ® NK cell engager molecules have the potential to strongly control tumor proliferation via the harnessing of NK cells Growing clinical pipeline Differentiated MoA SAR443579 / IPH6101 (CD123) Phase 1 / 2 ANKET3 Nature Biotechnology SAR’514 / IPH6401 (BCMA) Phase 1 / 2 January 2023 IPH650
Slide 11: SAR443579 / IPH6101 promising preliminary single agent clinical activity in R/R AML
ANKET® SAR443579 / IPH6101 promising preliminary single agent clinical activity in R/R AML SAR443579 / IPH6101 is a trifunctional anti-CD123 NKp46xCD16 NK cell engager PHASE 1 / 2 underway in R/R AML, B-cell ALL or HR MDS 82 patients to be enrolled Preliminary efficacy results 43 patients (42 R/R AM
Slide 12: Strategic partnership between Sanofi and Innate
ANKET® Strategic partnership between Sanofi and Innate Four molecules licensed to Sanofi plus one undisclosed targets remaining under option IPH6101/SAR’579 IPH6401/SAR’514 IPH62 IPH67 OPTION Ongoing CD123 BCMA B7-H3 Target Target programs Phase 1 / 2 in AML Phase 1 / 2 in Multiple Myeloma Research
Slide 13: We are leveraging our antibody expertise by developing differentiated ADCs
ADC We are leveraging our antibody expertise by developing differentiated ADCs ADC Research pipeline – Lead asset at pre-IND stage IPH45 (Nectin-4) Pre-IND IPH43 (MICA/B) Phase 1 Research Target (Tumor antigen) Research Target (Celiac disease) Research
Slide 14: IPH45 selected for an oral presentation at AACR 2024
ADC IPH45, our lead program targeting Nectin-4 has been selected for an oral presentation at the upcoming AACR 2024 Unique epitope, non-overlapping with enfortumab vedotin (EV) Cleavable hydrophilic linker High DAR and Topoisomerase I inhibitor with bystander effect April 9, 2024 3:35 - 3:50 PM Anti
Slide 15: Monalizumab development in progress of Phases 2 and 3 trials
MONALIZUMAB Monalizumab development in progress of Phases 2 and 3 trials Covering early stages of lung cancer Stages of the disease NeoCOAST* Data presented: 2022 NeoCOAST-2* 30% major pathological Patients with Stage II to IIIB NSCLC NSCLC response vs. 11% durvalumab. Monalizumab + durvalumab + che
Slide 16: 2023 Financial highlights
2023 Financial highlights Revenue/other income from continuing Operating expenses from Cash, cash equivalents and financial operations: continuing operations: assets €61.6m (excluding 2023 Sanofi €15m) €74.3m €102.3m* LICENSING AND COLLABORATIONS 75% expenses related to R&D €51.9m €102.3m* as of Dec
Slide 17: Newsflow and upcoming catalysts
Newsflow and upcoming catalysts • Monalizumab PACIFIC-9 | Phase 3 readout (AZ) Delivering across our strategic objectives • Monalizumab NeoCOAST-2 | Phase 2 readout (AZ) • IPH5201 (CD39) MATISSE | Phase 2 readout (AZ) • IPH5301 (CD73) | Phase 1 data • SAR’579 / IPH6101 ANKET® (CD123) | Next steps (S
Slide 18: Key Takeaways
Key Takeaways Create value for patients and shareholders Established expertise in immuno-pharmacology • LACUTAMAB FINAL DATA • Positive final results of TELLOMAK Phase 2 trial in Sézary syndrome • Final data in mycosis fungoides to be shared at an upcoming medical congress • EXPAND ANKET ® CLINICAL
Slide 19: Thank you
Thank you www.innate-pharma.com investors@innate-pharma.fr EURONEXT : IPH.PA NASDAQ : IPHA